$200M Singapore plant will be Amgen's first in Asia

01/18/2013 | Reuters

Amgen plans to invest about $200 million to construct a manufacturing plant at the Tuas Biomedical Park in Singapore. Work on the facility, Amgen's first in Asia, is expected to start within months. The plant's first products will be antibody drugs.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Corporate Counsel - Healthcare Law Group
Genentech
South San Francisco, CA
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD
Counsel – Regulatory Affairs
RAI Services Company
Winston Salem, NC
Senior Manager, Clinical Affairs - Advanced Technology
Edwards Lifesciences
Irvine, CA
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park